ERBB2 and neoplasm: It has been shown that the ligand portion (including trastuzumab, pertuzumab, affinity, and peptides) of the HER2-targeting radioactive molecular probes is responsible for the specific detection of HER2-positive tumor cells by targeting and binding to the extracellular domains IV or II of HER2 (Carter et al. 1992).